Physician profile
Robert E Younger
NPI 1629017819
$36,266.98
in general payments reported to CMS, 2019-2025
30 companies · $31.03 in 2025
The $31.03 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $3,576 · 2021: $6,097 · 2022: $5,682 · 2023: $2,421 · 2024: $1,216 · 2025: $31.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $27,673.62 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $4,493.98 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $726.28 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $587.86 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $531.49 | 2021-2024 | Cuvitru, Hyqvia, Glassia |
| Genzyme Corporation | $373.46 | 2019-2024 | |
| Csl Behring | $248.85 | 2019-2025 | Hizentra, Haegarda |
| Pfizer INC. | $217.63 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $197.84 | 2019-2024 | |
| Grifols USA, LLC | $167.29 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $148.16 | 2021-2024 | |
| Kaleo, INC. | $127.93 | 2019-2024 | Auvi-Q |
| Octapharma USA, INC. | $126.62 | 2021-2022 | |
| Amgen INC. | $82.74 | 2022-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $65.94 | 2019 | |
| Mylan Specialty L.P. | $65.29 | 2019 | |
| Pharming Healthcare, INC. | $49.62 | 2023-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $41.91 | 2021-2023 | Orladeyo |
| Hikma Pharmaceuticals USA | $33.53 | 2023-2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $32.96 | 2021-2022 | |
| Alcon Vision LLC | $31.14 | 2020 | |
| Dermavant Sciences, INC. | $24.67 | 2024 | Vtama |
| Alk-Abello, INC | $23.66 | 2021 | |
| Phadia US INC. | $22.61 | 2024 | Immunocap |
| Horizon Therapeutics Plc | $21.15 | 2020 | |
| Aimmune Therapeutics, INC. | $20.65 | 2022 | |
| Incyte Corporation | $18.30 | 2022 | |
| Merck Sharp & Dohme LLC | $18.11 | 2023 | |
| Adma Biomanufacturing LLC | $16.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Younger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.